NCT03967522 - Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2019

Primary Completion Date

October 22, 2024

Study Completion Date

November 1, 2024

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG

Cabozantinib

All participants will be treated by 60 mg of cabozantinib once daily. Temporary or permanent discontinuation and/or dose reduction of cabozantinib therapy may be required for the management of some adverse reactions. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.

Trial Locations (12)

25030

CHU Besancon, Besançon

31059

IUCT-Institut Claudius Regaud, Toulouse

33075

CHU Bordeaux, Bordeaux

44805

Institut de Cancérologie de l'Ouest-site René Gauducheau, Saint-Herblain

49005

Institut de Cancérologie de l'Ouest-Site Paul Papin, Angers

54519

Institut de Cancérologie de la Lorraine, Nancy

63011

Centre Jean Perrin, Clermont-Ferrand

67000

ICANS, Strasbourg

69373

Centre Leon Berard, Lyon

75015

Hopital Européen Georges Pompidou, Paris

92150

Hopital Foch, Suresnes

94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors

lead

Centre Leon Berard

OTHER